Bio-Techne Corp $TECH Stock Sold by Fifth Third Bancorp

Fifth Third Bancorp decreased its position in shares of Bio-Techne Corp (NASDAQ:TECH – Free Report) by 75.2% during the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 29,079 shares of the biotechnology company’s stock after selling 88,292 shares during the period. Fifth Third Bancorp’s holdings in Bio-Techne were worth $2,107,000 at the end of the most recent reporting period.

Other hedge funds have also recently added to or reduced their stakes in the company. Tema ETFs LLC increased its position in shares of Bio-Techne by 5.4% during the 2nd quarter. Tema ETFs LLC now owns 2,818 shares of the biotechnology company’s stock valued at $199,000 after purchasing an additional 145 shares during the last quarter. ZWJ Investment Counsel Inc. raised its holdings in shares of Bio-Techne by 4.8% during the 3rd quarter. ZWJ Investment Counsel Inc. now owns 3,971 shares of the biotechnology company’s stock valued at $288,000 after buying an additional 183 shares in the last quarter. Empirical Finance LLC raised its holdings in shares of Bio-Techne by 4.4% during the 2nd quarter. Empirical Finance LLC now owns 4,478 shares of the biotechnology company’s stock valued at $316,000 after buying an additional 189 shares in the last quarter. North Dakota State Investment Board lifted its position in Bio-Techne by 4.3% in the 3rd quarter. North Dakota State Investment Board now owns 4,789 shares of the biotechnology company’s stock worth $347,000 after buying an additional 196 shares during the last quarter. Finally, Parallel Advisors LLC lifted its position in Bio-Techne by 13.2% in the 1st quarter. Parallel Advisors LLC now owns 1,936 shares of the biotechnology company’s stock worth $101,000 after buying an additional 225 shares during the last quarter. Institutional investors own 98.95% of the company’s stock.

Wall Street Analyst Weigh In

Several analysts have issued reports on TECH shares. Benchmark reaffirmed a “hold” rating on shares of Bio-Techne in a research note on Wednesday, August 19th. Wells Fargo & Company cut shares of Bio-Techne from an “overweight” rating to an “equal weight” rating and increased their price target for the company from $62.00 to $73.00 in a research report on Thursday, August 13th. Zacks Research raised shares of Bio-Techne from a “hold” rating to a “strong-buy” rating in a research note on Thursday, October 29th. Argus cut Bio-Techne from a “strong-buy” rating to a “strong sell” rating in a research note on Monday, October 26th. Finally, Weiss Ratings raised Bio-Techne from a “hold (c-)” rating to a “hold (c)” rating in a research note on Tuesday, August 25th. One analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating, fourteen have given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, Bio-Techne currently has an average rating of “Hold” and a consensus price target of $69.00.

Check Out Our Latest Report on TECH

Bio-Techne Price Performance

TECH stock opened at $72.69 on Friday. Bio-Techne Corp has a 1 year low of $43.19 and a 1 year high of $72.88. The company has a market cap of $11.42 billion, a P/E ratio of 66.68, a price-to-earnings-growth ratio of 5.27 and a beta of 1.29. The stock’s fifty day moving average price is $72.58 and its 200-day moving average price is $63.68.

Bio-Techne (NASDAQ:TECH – Get Free Report) last released its quarterly earnings data on Monday, November 9th. The biotechnology company reported $0.44 earnings per share for the quarter, hitting analysts’ consensus estimates of $0.44. Bio-Techne had a return on equity of 13.00% and a net margin of 13.95%. The firm had revenue of $299.71 million during the quarter, compared to analyst estimates of $292.60 million. As a group, analysts expect that Bio-Techne Corp will post 1.75 earnings per share for the current year.

Bio-Techne Cuts Dividend

The company also recently announced a quarterly dividend, which will be paid on Monday, November 23rd. Shareholders of record on Friday, November 13th will be given a dividend of $0.08 per share. This is a drop from Bio-Techne’s previous quarterly dividend of $0.65. The ex-dividend date of this dividend is Friday, November 13th. This represents a $0.32 dividend on an annualized basis and a yield of 0.4%. Bio-Techne’s dividend payout ratio is presently 29.36%.

Bio-Techne Company Profile

(Free Report)

Bio-Techne is a life sciences company that develops and supplies products and services used in biological research, drug development, and clinical diagnostics. Its offerings include proteins, antibodies, immunoassays, and small molecules, as well as instruments and analytical tools for studying cells and biological processes. The company also provides technologies for protein analysis, molecular diagnostics, and spatial biology. Its portfolio includes products and services associated with brands such as R&D Systems, Tocris, ProteinSimple, and Advanced Cell Diagnostics.

Recommended Stories

Institutional Ownership by Quarter for Bio-Techne (NASDAQ:TECH)

Receive News & Ratings for Bio-Techne Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bio-Techne and related companies with MarketBeat.com's FREE daily email newsletter.